AbbVie Inc. (ABBV)
USD 173.02
(-1.35%)
USD 173.02
(-1.35%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 24.83 Billion USD | 28.81% |
| 2022 | 21.82 Billion USD | 9.87% |
| 2021 | 19.86 Billion USD | 11.25% |
| 2020 | 17.85 Billion USD | 43.32% |
| 2019 | 12.45 Billion USD | -31.65% |
| 2018 | 18.22 Billion USD | 61.93% |
| 2017 | 11.25 Billion USD | 10.14% |
| 2016 | 10.22 Billion USD | -4.23% |
| 2015 | 10.67 Billion USD | -9.34% |
| 2014 | 11.77 Billion USD | 43.43% |
| 2013 | 8.2 Billion USD | 5.66% |
| 2012 | 7.76 Billion USD | -8.75% |
| 2011 | 8.51 Billion USD | 34.78% |
| 2010 | 6.31 Billion USD | 24.9% |
| 2009 | 5.05 Billion USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.23 Billion USD | -29.36% |
| 2024 Q3 | 6.46 Billion USD | -10.95% |
| 2024 Q2 | 7.2 Billion USD | 37.55% |
| 2023 Q2 | 4.83 Billion USD | -9.19% |
| 2023 Q4 | 7.41 Billion USD | 45.55% |
| 2023 FY | 28.11 Billion USD | 28.81% |
| 2023 Q1 | 5.32 Billion USD | 2.21% |
| 2023 Q3 | 5.09 Billion USD | 5.44% |
| 2022 Q1 | 4.62 Billion USD | -9.1% |
| 2022 Q3 | 5.14 Billion USD | -24.85% |
| 2022 Q4 | 5.2 Billion USD | 1.15% |
| 2022 FY | 21.82 Billion USD | 9.87% |
| 2022 Q2 | 6.84 Billion USD | 48.12% |
| 2021 Q2 | 4.89 Billion USD | 5.93% |
| 2021 Q3 | 5.25 Billion USD | 7.31% |
| 2021 Q4 | 5.08 Billion USD | -3.22% |
| 2021 FY | 19.86 Billion USD | 11.25% |
| 2021 Q1 | 4.62 Billion USD | -9.71% |
| 2020 Q3 | 4.55 Billion USD | -10.9% |
| 2020 Q4 | 5.12 Billion USD | 12.5% |
| 2020 FY | 17.85 Billion USD | 43.32% |
| 2020 Q2 | 5.1 Billion USD | 66.2% |
| 2020 Q1 | 3.07 Billion USD | 18.09% |
| 2019 FY | 12.45 Billion USD | -31.65% |
| 2019 Q1 | 2.96 Billion USD | -64.76% |
| 2019 Q2 | 2.94 Billion USD | -0.81% |
| 2019 Q3 | 3.94 Billion USD | 33.85% |
| 2019 Q4 | 2.6 Billion USD | -33.97% |
| 2018 Q1 | 3.03 Billion USD | -9.48% |
| 2018 FY | 18.22 Billion USD | 61.93% |
| 2018 Q4 | 8.42 Billion USD | 164.32% |
| 2018 Q3 | 3.18 Billion USD | -11.03% |
| 2018 Q2 | 3.58 Billion USD | 18.02% |
| 2017 Q1 | 2.5 Billion USD | -11.96% |
| 2017 FY | 11.25 Billion USD | 10.14% |
| 2017 Q4 | 3.35 Billion USD | 25.39% |
| 2017 Q2 | 2.72 Billion USD | 8.95% |
| 2017 Q3 | 2.67 Billion USD | -1.94% |
| 2016 Q3 | 2.48 Billion USD | -3.98% |
| 2016 Q4 | 2.84 Billion USD | 14.31% |
| 2016 FY | 10.22 Billion USD | -4.23% |
| 2016 Q1 | 2.3 Billion USD | -18.17% |
| 2016 Q2 | 2.59 Billion USD | 12.56% |
| 2015 Q3 | 2.89 Billion USD | 7.75% |
| 2015 FY | 10.67 Billion USD | -9.34% |
| 2015 Q4 | 2.81 Billion USD | -2.77% |
| 2015 Q2 | 2.68 Billion USD | 17.51% |
| 2015 Q1 | 2.28 Billion USD | -51.61% |
| 2014 Q2 | 2.28 Billion USD | 8.05% |
| 2014 Q1 | 2.11 Billion USD | -5.97% |
| 2014 FY | 11.77 Billion USD | 43.43% |
| 2014 Q4 | 4.72 Billion USD | 96.09% |
| 2014 Q3 | 2.4 Billion USD | 5.48% |
| 2013 Q4 | 2.24 Billion USD | 13.72% |
| 2013 Q3 | 1.97 Billion USD | -6.62% |
| 2013 Q2 | 2.11 Billion USD | 13.04% |
| 2013 Q1 | 1.87 Billion USD | -10.55% |
| 2013 FY | 8.2 Billion USD | 5.66% |
| 2012 Q1 | 1.88 Billion USD | -1.06% |
| 2012 FY | 7.76 Billion USD | -8.75% |
| 2012 Q2 | 1.88 Billion USD | -0.05% |
| 2012 Q3 | 1.89 Billion USD | 0.53% |
| 2012 Q4 | 2.09 Billion USD | 10.2% |
| 2011 Q1 | 1.76 Billion USD | 0.0% |
| 2011 Q3 | 3.2 Billion USD | 96.62% |
| 2011 Q4 | 1.9 Billion USD | -40.46% |
| 2011 Q2 | 1.63 Billion USD | -7.61% |
| 2011 FY | 8.51 Billion USD | 34.78% |
| 2010 FY | 6.31 Billion USD | 24.9% |
| 2009 FY | 5.05 Billion USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bristol-Myers Squibb Company | 34.31 Billion USD | 27.622% |
| Bristol-Myers Squibb Company Ce | 34.31 Billion USD | 27.622% |
| Johnson & Johnson | 58.6 Billion USD | 57.624% |
| Eli Lilly and Company | 16.71 Billion USD | -48.566% |
| Merck & Co., Inc. | 43.98 Billion USD | 43.543% |
| Novartis AG | 24.87 Billion USD | 0.145% |
| Organon & Co. | 2.41 Billion USD | -926.664% |
| Pfizer Inc. | 25.45 Billion USD | 2.417% |